Talphera Inc (TLPH) Stock Analysis

AI analysis of Talphera Inc (TLPH)

Sell

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.

Valuation Metrics

The current forward P/E ratio for Talphera Inc (TLPH) is 1.02, compared to its 5-year average forward P/E of -0.85.

Forward P/E

Overvalued

5Y Average P/E

-0.85

Current P/E

1.02

Overvalued

0.50

Undervalued

-2.19

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.32

Current EV/EBITDA

-0.01

Overvalued

0.83

Undervalued

-1.48

Forward P/S

Fair

5Y Average P/S

507.28

Current P/S

121.93

Overvalued

2323.26

Undervalued

-1308.69

Alphio AI Price Scenarios for TLPH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TLPH

$0.50

Scenario price

B

Base

Base · 50%TLPH

$0.49

Scenario price

B

Bear

Bear · 25%TLPH

$0.40

Scenario price

TLPH FAQ — answered by Alphio AI

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Talphera Inc is not a good buy right now due to its current price of $1.01 and a very low RSI of 22.51, indicating oversold conditions. The company has reported significant losses, with a net income of -4.43 million USD in Q3 2025 and a forward P/E ratio of 1.02, which is unusually low but reflects the company's ongoing financial struggles. Although analysts have a price target of $3, the stock has decreased by 28.37% over the past year, and the recent performance shows a 5-day change of -5.61%. The main risk is the company's high net loss and reliance on future financing, as indicated by a cash position decrease from $21.1 million to $17.1 million in just a few months, which raises concerns about its operational sustainability.